Please use this identifier to cite or link to this item:
http://repo.knmu.edu.ua/handle/123456789/27474Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Koshkina, Marharyta | - |
| dc.contributor.author | Кошкіна, Маргарита Володимирівна | - |
| dc.date.accessioned | 2020-11-23T19:08:51Z | - |
| dc.date.available | 2020-11-23T19:08:51Z | - |
| dc.date.issued | 2020-10 | - |
| dc.identifier.citation | Koshkina M. Justification for valsartan and telmisartan prescribing to patients with coronary artery disease and diabetes melitus type 2 / M. Koshkina // ISIC-2020 : [International Scientific Interdisciplinary Conference for medical students and young scientists, Kharkiv, 8–9 October, 2018]: abstract book / KNMU. – Kharkiv, 2020. – P. 70. | en_US |
| dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/27474 | - |
| dc.description.abstract | Introduction: It is known that there is a need to prescribe blood pressure control drugs to patients with coronary artery disease (CAD). Among them there is the reninangiotensin-aldosterone system blockers group (ARBs). There is evidence that the designation of ARBs improves predictions of the progress of CAD. | en_US |
| dc.language.iso | en | en_US |
| dc.subject | coronary artery disease | en_US |
| dc.subject | type 2 diabetes mellitus | en_US |
| dc.title | Justification for valsartan and telmisartan prescribing to patients with coronary artery disease and diabetes melitus type 2 | en_US |
| dc.type | Thesis | en_US |
| Appears in Collections: | Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 2 і клінічної імунології та алергології ім. ак. Л.Т. Малої | |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.